Promethera Biosciences is a biotechnology company developing regenerative medicine treatments for liver diseases that is headquartered in Mont-Saint-Guibert, Belgium and was founded in 2009 by Etienne Sokal.
The company is a spin-off of the Universita Catholique de Louvain, and is interested in developing treatments based on allogenic adult stem cell technology. They look to commercialize cell therapy products to treat liver diseases using progenitor cells from healthy human livers. The progenitor cells that Promethera Biosciences are adult liver-derived mesenchymal progenitor cells.
Promethera Biosciences looks to develop new cell and antibody-based therapies for the treatment of liver diseases. The company has developed a cell-based therapy called HepaStem, which has potential to provide novel treatment options for chronic and acute live diseases. This could be successful for Acute-on-Chronic Liver Failure, fibrosis, and non-alcoholic SteatoHepatitis. The HepaStem can be administered intravenously, transported through the bloodstream to the liver, and provide it a chance to repair and regenerate. It reduces inflammation processes as well as fibrogenesis, as it inhibits hepatic stellate cell activation and collagen secretion, and degrades the excessive extracellular matrix.
Another product of Promethera Biosciences is the H2Stem. The H2Stem is used to display a high capacity for homing, in situ differentiation into hepatocytes and repopulation after their transplantation in a model of human xenografts.
The company's third and fourth product are the antibody-based drug candidates which includes the Atrosab and Atrosimab. These products target the pro-inflammatory tumor necrosis factor receptor 1, and blocks its activation by TNF-alpha without interacting with the TNF receptor 2.
CFO EU / US Financial Operations
Founder, Chief Scientific & Medical Officer
Henrik L. Luessen
Chief Business Officer
President & CEO
MBA, CCO Promethera Biosciences Group (Belgium) & Managing Director of Promethera Bisociences LLC (USA)
Group Chief Financial Officer , Branch General Manager of Promethera Biosciences Japan Branch
VP Product Development
VP Regulatory Affairs
cGMP Compliance Status for Promethera Biosciences’ Production Site in Durham, NC Confirmed by Health Canada
Promethera Biosciences Announces Investment by ITOCHU Corporation and a Broad Strategic Collaboration to Access the Asian Markets
Promethera Biosciences Raised €25,33M to Treat Liver Diseases
Promethera Biosciences Raised Additional EUR 9.3 Million to Advance a Broad Product Pipeline in Severe Liver Diseases
Documentaries, videos and podcasts
- Cluster: BiotechnologyA cluster of topics related to biotechnology.
- Cluster: Stem cell technologyTechnology used for isolating, generating, growing and controlling the differentiation of stem cells into specialized cells and the application of stem cell technology for medical and non-medical purposes such as producing meat through cellular agriculture.
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.
- Stem cellStem cells are self-renewing cells that have the potential to become multiple different cell types in the body. Stem cells are found in developing embryos. Adult stem cells maintain and repair tissues throughout life. Induced pluripotent stem cells are a type of stem cell derived from adult cells that are reprogrammed in the lab.